Summary
53 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: 138.4M zł against 25.0M zł.
- Out of every 100 PLN of revenue, 11 PLN is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 1.9% a year over the last 3 years.
- It earns only 4.5 PLN a year on every 100 PLN of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 8.1 PLN for 1 PLN of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (PLN)
Diluted EPS (PLN)
Revenue fell by 21% a year over 5 years. Over the last 3 years it grew by 1.9% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 PLN of revenue goes
- Cost of sales 73 PLN
- Sales and administration 19 PLN
- Taxes and other -2.9 PLN
- Net profit 11 PLN
Net profit, industry median (Medical - Instruments & Supplies) 8.2 PLN
Out of every 100 PLN of revenue, 11 PLN is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.1 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Moderate, safe- Yield
- 2.78%
- Paid out of profit
- 23%
You receive 1.64 zł per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail